Psoriatic Arthritis News

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Depression and anxiety among patients with inflammatory arthritis is significantly undertreated, with large proportions not receiving minimally adequate care, according to data published in Arthritis Research & Therapy.

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for physicians, who highly prioritized individual symptoms, according to data published in ACR Open Rheumatology.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated with tumor necrosis factor inhibitors.